Back to Search
Start Over
The addition of metformin to systemic anticancer therapy in advanced or metastatic cancers: a meta-analysis of randomized controlled trials
- Source :
- International Journal of Medical Sciences
- Publication Year :
- 2020
- Publisher :
- Ivyspring International Publisher, 2020.
-
Abstract
- Preclinical studies have demonstrated that metformin has anticancer properties and act in additive or synergistic way when combined with anticancer agents. We conducted this meta-analysis of randomized clinical trials to evaluate the effect of metformin added to systemic anticancer therapy in patients with advanced or metastatic cancer. A computerized systematic electronic search was performed using PubMed, PMC, EMBASE, Cochrane Library, and Web of Science databases (up to June 2020). From nine randomized clinical trials, 821 patients were included in the pooled analyses of odds ratios (ORs) with 95% confidence intervals (CIs) for overall response rate (ORR) and hazard ratios (HRs) with 95% CIs for progression-free survival (PFS) and overall survival (OS). The concomitant use of metformin with systemic anticancer therapy did not increase tumor response (the pooled OR of ORR = 1.23, 95% CI: 0.89-1.71, p = 0.21), compared with anticancer therapy alone. In terms of survival, metformin added to anticancer agents failed to prolong PFS (HR = 0.95, 95% CI: 0.75-1.21, p = 0.68) and OS (HR = 0.97, 95% CI: 0.80-1.16, p = 0.71). In conclusion, this meta-analysis of randomized clinical trials indicates that the addition of metformin to systemic anticancer therapy has no clinical benefits in patients with advanced or metastatic cancer.
- Subjects :
- Oncology
medicine.medical_specialty
Time Factors
randomized controlled study
Cochrane Library
law.invention
03 medical and health sciences
0302 clinical medicine
Randomized controlled trial
law
Neoplasms
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
cancer
Neoplasm Metastasis
Neoplasm Staging
Randomized Controlled Trials as Topic
business.industry
Hazard ratio
Cancer
General Medicine
Odds ratio
medicine.disease
Metformin
Progression-Free Survival
meta-analysis
Meta-analysis
Concomitant
030211 gastroenterology & hepatology
prognosis
business
Research Paper
medicine.drug
Subjects
Details
- ISSN :
- 14491907
- Volume :
- 17
- Database :
- OpenAIRE
- Journal :
- International Journal of Medical Sciences
- Accession number :
- edsair.doi.dedup.....e658b3db3049fce67ddc1170487813e4